{"product_id":"argotone-1-0-9-20-ml-gocce-nasali-soluzione","title":"Argotone 1% + 0.9% 20 ml nasal drops solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAntiseptic and nasal decongestant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml of solution contains: - Vitellinate silver 1 g - Ephedrine hydrochloride 0.9 g For the complete list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Sodium chloride - Anhydrous sodium thiosulphate - Purified water\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active ingredients, to sympathomimetic amines in general or to any of the excipients listed in paragraph 6.1, Heart disease and severe arterial hypertension, Glaucoma, Prostatic hypertrophy, Hyperthyroidism, Pheochromocytoma. Do not administer during or in the two weeks following therapy with monoamine oxidase inhibitors (MAOIs). The drug is contraindicated in children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdults and children over 12 years: 3 drops in each nostril 2-3 times a day. Treatment must not be continued for more than 7 days. Carefully follow the recommended doses. A higher dosage of the product, even if taken topically and for a short period of time, can give rise to serious systemic effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTHIS MEDICINAL PRODUCT DOES NOT REQUIRE ANY SPECIAL STORAGE CONDITIONS For storage conditions after first opening see section 6.3\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn patients with cardiovascular diseases, and in hypertensive patients, the use of nasal decongestants must be subject to the doctor's judgment from time to time. Cardiovascular effects may be observed with the use of sympathetic mimetic drugs, such as Argotone. There is evidence, from post-marketing data and published literature, of rare cases of myocardial ischemia in association with the use of beta agonists. Patients taking Argotone should be advised to seek medical advice if they experience chest pain or other symptoms of worsening of a pre-existing heart condition. Attention should be paid to the evaluation of symptoms such as dyspnea and chest pain, as they can be of both respiratory and cardiac origin. The prolonged use of vasoconstrictors can alter the normal function of the mucosa of the nose and paranasal sinuses, also inducing addiction to the drug. Repeating applications for longer periods than recommended can, therefore, be harmful. Use with caution in diabetics and, due to the risk of urinary retention, in elderly subjects. The use of topical products, especially if prolonged, can give rise to sensitization phenomena; in this case it is necessary to interrupt treatment and, if necessary, institute appropriate therapy. In the absence of a complete therapeutic response within a few days, consult your doctor; in any case, the treatment must not be continued for more than a week. Carefully follow the recommended doses. The medicine, if accidentally ingested or if used for a long period in excessive doses, can cause toxic phenomena. It should be kept out of the reach of children. It should not be used orally. Avoid contact of the liquid with the eyes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEphedrine reduces the plasma half-life of corticosteroids. Asthma patients being treated with these drugs should therefore avoid taking ephedrine-based products. Ephedrine contained in ARGOTONE can interact negatively with monoamine oxidase inhibitors (MAOIs). The administration of the product during or in the two weeks following antidepressant drug therapy is consequently contraindicated. Ephedrine may reduce the pharmacological effectiveness of antihypertensive drugs; associated with clonidine, it can cause an increase in norepinephrine levels and an increase in blood pressure with an increased risk of arrhythmias. Urinary excretion of ephedrine is pH dependent; acetazolamide, antacids, ammonium chloride and sodium bicarbonate are able to alkalinize the urine, and consequently slow down the elimination of ephedrine. The contemporary association of ephedrine with digoxin, phenylpropanolamine, cyclopropane and pseudoephedrine is associated with a greater risk of adverse cardiovascular events (increased risk of arrhythmias). Reserpine, causing norepinephrine depletion, may reduce the effectiveness of ephedrine. Theophylline may cause a greater incidence of central and gastrointestinal adverse effects, which occur following the administration of ephedrine. Thyroid hormones: Caution is required in the concomitant use of sympathetic mimetics and thyroid hormones. Volatile anaesthetics: Ephedrine should be avoided in patients undergoing anesthetic treatment with halogenated anaesthetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine can cause local sensitization or rebound mucous congestion phenomena. The following side effects have been reported with the use of systemic ephedrine and may occur following the use of ephedrine-based nasal drops. Undesirable effects are described according to system organ class according to MedDRA and on the basis of the frequency estimated from post-marketing experience. Frequencies are defined as follows: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon: (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003eNervous system disorders\u003c\/b\u003e Not known: Headache, restlessness, insomnia, tolerance \u003cb\u003eCardiac diseases\u003c\/b\u003e Not known: Tachycardia, palpitations, myocardial ischemia \u003cb\u003eVascular pathologies\u003c\/b\u003e Not known: Hypertension \u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e Not known: Dyspnoea \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e Not known: Nocturia in patients with prostate hyperplasia, urinary retention \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Not known: Hyperhidrosis, rash \u003cb\u003eImmune system disorders\u003c\/b\u003e Not known: Hypersensitivity \u003cb\u003eReporting of suspected adverse reactions \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn case of overdose (e.g. accidental oral intake), central depression and sedation, i.e. episodes of excitement with agitation, hypertensive crisis and facial congestion, may appear in children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable not to use the drug during pregnancy or while breastfeeding. \u003cb\u003ePregnancy\u003c\/b\u003e Ephedrine crosses the placental barrier and has been associated with increased fetal heart rate. \u003cb\u003eBreastfeeding \u003c\/b\u003e Ephedrine is present in breast milk. The effects on infants are unknown: it has been reported that ephedrine can cause irritability and disturbed sleep in infants when used during breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot known.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":51730202755399,"sku":"003950019","price":8.55,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dompe-farmaceutici-spa-argotone-1-0-9-20-ml-gocce-nasali-soluzione-farmacia-dottor-tili-1213791444.jpg?v=1767138191","url":"https:\/\/www.dottortili.com\/en-eu\/products\/argotone-1-0-9-20-ml-nasal-drops-solution","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}